Attorney Docket No. 5168

IAP5 Rec'd PCT/PTO 27 JAN 2886ENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chengzhi Zhang, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/US2004/025480

Title: Benzofuran Derivatives Useful for Treating Hyper-Proliferative Disorders

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA. VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

William F. Gray Reg. No.: 31,018

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-2226

Facsimile: (203) 812-6459

IAP5 Rec'd PCT/PTO 2 7 JAN 2006 10/566343

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449/PTO				Complete if Known		
				Application Number	[to be assigned]	
INIE	ORMATION	LDISC	LOCUBE	Filing Date		
	- -			First Named Inventor	Chengzhi Zhang	
STA	ATEMENT I	3Y API	PLICANT	Art Unit		
(Use as many sheets as necessary)				Examiner Name		
heet	1	of	2	Attorney Docket Number	5168	

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-			
	-	US-	-		
		US-			
_		US-			
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	₽
/N.C./	F1	WO 03/072561 A1	09-04-2003	Bayer Pharmaceuticals	Corporation	
(),()	, F2	EP 0/731/097 A1	09-11-1996	Eli Lilly and Company		
/N.C.		111101				
				-		_
	ļ					╙
	1					ı

Examiner	Date	
Signature	Considered	
	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language

Translation is a stateched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IAP5 Rec'd PCT/PTO 27 JAN 2006

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

7 PP 10 10 10 10 10 10 10 10 10 10 10 10 10
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMER
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb

Substitute for form 1449/PTO				Complete if Known			
				Application Number	[to be assigned] / 566343		
INFO	DRMATION	I DIS	CLOSURE	Filing Date	300347		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Chengzhi Zhang		
	///	4		Art Unit			
(Use as many sheets as necessary)				Examiner Name			
Sheet	2	of	2	Attorney Docket Number	5168		

-			
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/N.C./	R1	Hayakawa, I., et al., "4-Hydroxy-3-methyl-6-phenylbenzofuran-2-carboxylic Acid Ethyl Ester Derivatives as Potent Anti-tumor Agents", Bioorg. Med. Chem. Lett. 14: 455-458 (2004)	
/N.(^{3./} R2	Hayakawa, I., et al., "Thienopyridine and Benzofuran Derivatives as Potent Anti-tumor Agents Possessing Different Structure-activity Relationships", Bioorg. Med. Chem. Lett. 14: 3411-3414 (2004)	
/N.C./	R3	Hayakawa, I., et al., "A Library Synthesis of 4-Hydroxy-3-Methyl-6-Phenylbenzofuran-2-carboxylic Acid Ethyl Ester Derivatives as Anti-tumor Agents", Bioorg. Med. Chem. Lett. 14: 4383-4387 (2004)	
	1		
	·		

Examiner	/Nizal Chandrakumar/	 Date	04/26/2008
Signature	/ retained Serial roll der (der roll)	Considered	İ
*EVALUED !		 	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.